Concepts (95)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 7 | 2023 | 532 | 1.210 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2025 | 5 | 0.980 |
Why?
|
| Folic Acid | 1 | 2020 | 292 | 0.610 |
Why?
|
| Embryonic Stem Cells | 1 | 2018 | 172 | 0.560 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2018 | 537 | 0.450 |
Why?
|
| Hemoglobinuria, Paroxysmal | 5 | 2024 | 19 | 0.410 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 3 | 2021 | 23 | 0.380 |
Why?
|
| Mutation | 5 | 2024 | 5777 | 0.310 |
Why?
|
| Signal Transduction | 1 | 2020 | 4508 | 0.300 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2024 | 118 | 0.270 |
Why?
|
| Prognosis | 3 | 2025 | 4508 | 0.240 |
Why?
|
| Disease Susceptibility | 1 | 2025 | 298 | 0.210 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2023 | 162 | 0.210 |
Why?
|
| Molecular Targeted Therapy | 1 | 2025 | 352 | 0.200 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2023 | 137 | 0.200 |
Why?
|
| Minors | 1 | 2021 | 6 | 0.200 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2021 | 64 | 0.190 |
Why?
|
| Refugees | 1 | 2021 | 32 | 0.190 |
Why?
|
| Tumor Microenvironment | 1 | 2025 | 538 | 0.180 |
Why?
|
| Disease Management | 1 | 2025 | 516 | 0.180 |
Why?
|
| Thrombocytopenia | 1 | 2023 | 229 | 0.180 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2021 | 121 | 0.180 |
Why?
|
| DNA, Neoplasm | 1 | 2021 | 300 | 0.180 |
Why?
|
| Histones | 2 | 2021 | 528 | 0.180 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 286 | 0.170 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2021 | 354 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 3 | 2011 | 1015 | 0.160 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2019 | 57 | 0.160 |
Why?
|
| Bone Marrow | 1 | 2020 | 322 | 0.160 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 142 | 0.150 |
Why?
|
| Antioxidants | 1 | 2020 | 337 | 0.150 |
Why?
|
| Nuclear Proteins | 2 | 2021 | 1267 | 0.140 |
Why?
|
| Chromosome Aberrations | 1 | 2020 | 614 | 0.140 |
Why?
|
| Glutamine | 1 | 2018 | 195 | 0.140 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 3287 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2012 | 502 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 519 | 0.110 |
Why?
|
| Disease Progression | 1 | 2019 | 2027 | 0.100 |
Why?
|
| Humans | 15 | 2025 | 123181 | 0.100 |
Why?
|
| Hemosiderin | 1 | 2012 | 2 | 0.100 |
Why?
|
| Iron Overload | 1 | 2012 | 15 | 0.100 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2011 | 38 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2307 | 0.090 |
Why?
|
| Animals | 4 | 2025 | 33732 | 0.090 |
Why?
|
| Complement C3 | 1 | 2009 | 47 | 0.080 |
Why?
|
| Neoplasms | 1 | 2023 | 2767 | 0.080 |
Why?
|
| Erythrocytes | 1 | 2009 | 206 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 4351 | 0.070 |
Why?
|
| Bone Marrow Diseases | 1 | 2024 | 39 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2009 | 655 | 0.060 |
Why?
|
| Forensic Sciences | 1 | 2021 | 2 | 0.050 |
Why?
|
| Principal Component Analysis | 1 | 2021 | 142 | 0.050 |
Why?
|
| Family | 1 | 2023 | 579 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2021 | 297 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2021 | 338 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 4266 | 0.040 |
Why?
|
| Mice | 3 | 2021 | 17492 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 353 | 0.040 |
Why?
|
| Software | 1 | 2023 | 677 | 0.040 |
Why?
|
| Middle Aged | 4 | 2024 | 25976 | 0.040 |
Why?
|
| THP-1 Cells | 1 | 2018 | 22 | 0.040 |
Why?
|
| DNA | 1 | 2023 | 1592 | 0.040 |
Why?
|
| K562 Cells | 1 | 2018 | 95 | 0.040 |
Why?
|
| Transduction, Genetic | 1 | 2019 | 288 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2019 | 258 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 657 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2019 | 715 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 2405 | 0.030 |
Why?
|
| Base Sequence | 1 | 2021 | 3093 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2018 | 619 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2019 | 576 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 1695 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2020 | 766 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 251 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2021 | 2820 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2020 | 3050 | 0.030 |
Why?
|
| Male | 5 | 2024 | 60018 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 1995 | 0.030 |
Why?
|
| Female | 5 | 2024 | 65426 | 0.030 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2011 | 7 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 1677 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2011 | 295 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 1650 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 4708 | 0.020 |
Why?
|
| Graft Survival | 1 | 2011 | 525 | 0.020 |
Why?
|
| Splenectomy | 1 | 2008 | 60 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2008 | 300 | 0.020 |
Why?
|
| Cell Survival | 1 | 2009 | 803 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2009 | 804 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 1114 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 3518 | 0.010 |
Why?
|
| Adult | 2 | 2012 | 29035 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 8868 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2012 | 12102 | 0.010 |
Why?
|
| Adolescent | 1 | 2012 | 19086 | 0.010 |
Why?
|